Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2023-04-11 Capital/Financing Update
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
FWP
Capital/Financing Update Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433 under a Registration Statement No. 333-269606. It relates to a proposed public offering of shares of common stock by MAIA Biotechnology, Inc. The text includes disclaimers about the registration statement, references to the SEC EDGAR system, and detailed information about the company's business, pipeline, clinical trials, and the offering. The document is a Free Writing Prospectus (FWP), which is a type of prospectus used in securities offerings to provide additional information to investors. This type of document is related to capital raising activities and financing updates. It is not a full financial report, earnings release, or regulatory filing unrelated to financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed information about the offering and company strategy, consistent with a capital/financing update.
2023-04-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about positive topline data from a clinical trial and recruitment commencement, furnished as Exhibit 99.1. The document explicitly states that the information is "furnished" and not "filed," indicating it is an announcement rather than a full report. The length is 3804 characters, which is relatively short and consistent with a current report rather than a full financial or annual report. There is no detailed financial data or comprehensive analysis present. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-04-11 English
FWP
Capital/Financing Update Classification · 100% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433, referencing a Registration Statement No. 333-269606. It discusses a proposed public offering of shares, includes disclaimers about the registration statement and prospectus, and provides detailed information about the company's business, pipeline, and clinical trials. The document is a Free Writing Prospectus (FWP), which is a type of offering document used in securities offerings to provide additional information to investors beyond the preliminary prospectus. It is not an annual report, earnings release, or any other financial report. It is also not a proxy, voting results, or management change announcement. The content focuses on the offering and investment overview, consistent with a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-04-07 English
PRIMARY DOCUMENT
Director's Dealing
2023-04-05 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a preliminary prospectus for an initial public offering (IPO) of common stock by MAIA Biotechnology, Inc. The text includes detailed information about the offering, company background, risk factors, use of proceeds, management, and other disclosures typical of an S-1 filing. This type of document is a registration statement for securities offering and does not fit into categories like Annual Report, Earnings Release, or Management Discussion. The closest fitting category from the provided list is 'Capital/Financing Update (CAP)' because it relates to company fundraising and capital structure changes through a public offering. The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or notice, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the appropriate classification is CAP with high confidence.
2023-04-04 English
PRIMARY DOCUMENT
Director's Dealing
2023-04-04 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.